Cosopt Adverse Reactions

In clinical studies, Cosopt was generally well tolerated; no adverse experiences peculiar to this combination drug have been observed. Adverse experiences have been limited to those that were reported previously with dorzolamide hydrochloride and/or timolol maleate. In general, common adverse experiences were mild and did not cause discontinuation.
During clinical studies, 1035 patients were treated with COSOPT. Approximately 2.4% of all patients discontinued therapy with Cosopt because of local ocular adverse reactions. Approximately 1.2% of all patients discontinued because of local adverse reactions suggestive of allergy or hypersensitivity. The most frequently reported drug-related adverse effects were: Ocular burning and stinging, taste perversion, corneal erosion, conjunctival injection, blurred vision, tearing and ocular itching. Urolithiasis was reported rarely.
The following adverse reactions have been reported in post-marketing experience: Dyspnea, respiratory failure, contact dermatitis, bradycardia, heart block and choroidal detachment following filtration surgery, nausea, Stevens-Johnson syndrome and toxic epidermal necrolysis.